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Abstract
Connective Tissue Growth Factor (CTGF) and Transforming growth factor-b1 (TGF-b1) are key growth factors in regulating
corneal scarring. Although CTGF was induced by TGF-b1 and mediated many of fibroproliferative effects of TGF-b1, the
signaling pathway for CTGF production in corneal scarring remains to be clarified. In the present study, we firstly
investigated the effects of c-Jun N-terminal kinase (JNK) on CTGF expression induce by TGF-b1 in Telomerase-immortalized
human cornea stroma fibroblasts (THSF). Then, we created penetrating corneal wound model and determined the effect of
JNK in the pathogenesis of corneal scarring. TGF-b1 activated MAPK pathways in THSF cells. JNK inhibitor significantly
inhibited CTGF, fibronectin and collagen I expression induced by TGF-b1 in THSF. In corneal wound healing, the JNK
inhibitor significantly inhibited CTGF expression, markedly improved the architecture of corneal stroma and reduced corneal
scar formation, but did not have a measurable impact on corneal wound healing in vivo. Our results indicate that JNK
mediates the expression of CTGF and corneal scarring in corneal wound healing, and might be considered as specific targets
of drug therapy for corneal scarring.
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Introduction
The cornea is a highly transparent tissue located at the anterior
surface of the eye. Corneal scarring caused by injury or surgery is
one of the main causes of blindness worldwide [1]. So far, there is
no effective and safe strategy for the prevention or inhibition of
corneal scar formation in clinical practice. Therefore, research on
how to reduce corneal scarring in corneal wound healing will be of
great clinical value.
TGF-b1 has been found to play an important role in promoting
fibrosis and scarring in numerous tissues [2]. Many of the scarring
effects of TGF-b1 are mediated by CTGF [3]. CTGF is a 38-kDa
secreted protein belongingto the CCNfamily[4],and its expression
is induced by TGF-b1 in cultured fibroblasts [5,6]. CTGF has
been shown to promote the synthesis of various constituents of the
extracellular matrix [7,8] and its over-expression can promote
fibrosis and scar formation in skin, kidney, liver, brain, lung, human
gingiva, vasculature and pancreas [9,10,11].
TGF-b1 and CTGF are key growth factors in regulating corneal
scarring [12,13]. We have previously shown that expression of
TGF-b1 and CTGF increased dramatically during corneal wound
healing, TGF-b1 could induce CTGF expression in vivo [14].
TGF-b1 played an important role in the activation of quiescent
corneal keratocytes [15], CTGF was induced by TGF-b1 and
mediated the effect of TGF-b1 on collagen, fibronectin synthesis
[16]. This was consistent with other reports in which TGF-b1
increased CTGF expression in human corneal fibroblasts [12].
Antisense oligonucleotides and neutralizing antibodies to CTGF
decrease TGF-b1 induced collagen synthesis, cell proliferation and
matrix contraction in corneal fibroblast [17,18]. CTGF plays a
critical role in mediating many of the important fibroproliferative
effects of TGF-b1 in corneal fibroblasts. Therefore, understanding
mechanisms regulating expression of CTGF increased by TGF-b1
is of great importance to inhibit corneal scarring.
SMAD proteins are the primary substrates of TGF-b1 receptors
[19], whereas we previously found that TGF-b1 up-regulated
CTGF expression was not via SMAD pathways in rabbit corneal
wound healing [14]. In addition to SMAD proteins, the mitogen-
activated protein kinase (MAPK) pathways were involved in TGF-
b1 signaling [20]. MAPK pathways are a family of serine-
threonine protein kinases that are activated in response to a variety
of extra cellular stimuli. Extracellular signal-regulated kinase
(ERK), JNK and p38 pathway constitute three major subfamilies
of MAPK pathways [21]. It has been shown that TGF-b1 can
activate the ERK [22], JNK [23] and p38 [24] pathway. There
is evidence that TGF-b1 induced CTGF expression is medi-
ated through JNK in human lung fibroblasts [25]. In gingival
fibroblasts, the sole MAPK mediates the TGF-b1 stimulated
CTGF expression was JNK [26]. ERK mediates TGF-b1 induced
CTGF expression in skin fibroblasts [27]. Inhibition of p38 could
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e32128suppress collagen I, fibronectin and CTGF expression induced by
TGF-b1 in conjunctival fibroblasts [28]. Our Previous studies
have shown that TGF-b1 induced the activation of JNK in corneal
fibroblast, inhibition of JNK pathway can effectively inhibit TGF-
b1 induced CTGF expression and subsequent corneal fibroblast
proliferation and collagen over-expression in corneal fibroblasts
[15]. However, the signaling pathway of CTGF production in
corneal wound healing remains unclear.
Based on these findings, it was hypothesized that MAPK
pathways could mediate CTGF expression and corneal scarring in
corneal wound healing. In the present study, we investigated
whether TGF-b1 could induced MAPK pathways phosphoryla-
tion in THSF cells, and determined the effect of the MAPK
pathways in TGF-b1 induced CTGF, fibronectin and collagen I
mRNA expression in THSF cells were investigated. Then, the
penetrating corneal wound model was created in vivo and the
effect of JNK on CTGF expression and corneal scarring in corneal
wound healing was identified.
Results
TGF-b1 induced MAPK pathways phosphorylation in
THSF cells
We investigated whether TGF-b1 could induce MAPK
pathways phosphorylation in THSF cells. THSF cells were treated
with 3 ng/ml of TGF-b1 for 15, 30, 60 and 120 minutes, followed
by extraction of the cellular protein. The expressions of total
and phosphorylated ERK1/2, p38, and JNK were determined by
Western blot analysis. As shown in Figure 1, THSF cells stimu-
lated with TGF-b1 induced a rapid increase in the phosphoryla-
tion of ERK, p38 and JNK. The maximum phosphorylation of
ERK was observed after 15 min of stimulation with TGF-b1.
While the maximum phosphorylation of p38 and JNK were
observed after 30 min of stimulation with TGF-b1.
Inhibitory effect of PD98059, SB203580 and SP600125 on
TGF-b1 induced MAPK pathways phosphorylation
The inhibitory effects of the three MAPK pathways-specific
inhibitors on TGF-b1 induced MAPK phosphorylation were
evaluated. THSF cells were pretreated with ERK inhibitor
(PD98059, 30 mM), p38 inhibitor (SB203580, 10 mM) or JNK
inhibitor (SP600125, 30 mM) for 1 h, respectively. Then the cells
were stimulated with TGF-b1 (3 ng/ml) for 15 min (ERK) or
30 min (p38, JNK). The expressions of total and phosphorylated
ERK1/2, p38, and JNK were determined by Western blot
analysis. As shown in Figure 2, TGF-b1 induced phosphorylation
of ERK, p38 or JNK were significantly inhibited by PD98059,
SB203580 or SP600125, respectively.
Effect of MAPK-specific inhibitors on expression and
secretion of CTGF induced by TGF-b1
To determine MAPK pathways requirements for the TGF-b1
induced CTGF expression, THSF cells were treated in the
absence or presence of ERK inhibitor (PD98059, 30 mM), p38
inhibitor (SB203580, 10 mM) or JNK inhibitor (SP600125, 30 mM)
for 1 h, respectively. TGF-b1 (3 ng/ml) was subsequently added to
the culture for 24 h. Expression of CTGF mRNA was determined
by real time PCR analysis. Figure 3 A shows that the presence of
SP600125 markedly inhibited CTGF mRNA expression. In
contrast, PD98059 and SB203580 showed weak effects on TGF-
b1 induced CTGF mRNA expression.
In addition, the concentration of CTGF secretions into the
medium was measured by ELISA analysis. As shown in Figure 3
B, compared with control, TGF-b1 significantly stimulated the
secretions of CTGF after 24 h treatment. SP600125 markedly
inhibited TGF-b1 stimulated CTGF secretion. However,
SB203580 or PD98059 had no effect on the secretion of CTGF
induced by TGF-b1.
Figure 1. TGF-b1 induced MAPK pathways phosphorylation in
THSF cells. THSF cells were incubated with TGF-b1 (3 ng/ml) for the
times indicated. The total and phosphorylation of ERK (A), p38 (B) and
JNK (C) MAPK were determined by using Western blot analysis. Data are
representative of three independent experiments. *, P,0.05 vs. control
cells without TGF-b1 stimulation.
doi:10.1371/journal.pone.0032128.g001
JNK Regulates Corneal Scarring
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fibronectin and collagen I induced by TGF-b1
Next, we determined if MAPK pathways play any role in
TGF-b1 induced fibronectin and collagen I expression. THSF
cells were pretreated with ERK inhibitor (PD98059, 30 mM),
p38MAPK inhibitor (SB203580, 10 mM) or JNK inhibitor
(SP600125, 30 mM) for 1 hour, respectively. Subsequently they
were treated with TGF-b1 (3 ng/ml) for 24 hour. Expression of
fibronectin and collagen I protein was determined by Western
blot analysis. As shown in Figure 4, TGF-b1 significantly up-
regulated expression of fibronectin and collagen I. Fibronectin
expression was markedly decreased in the presence of SP600125
or SB203580. In contrast, no significant influence of PD98059 on
fibronectin expression was observed. In addition, expression of
collagen I was markedly attenuated by SP600125, whereas
PD98059 or SB203580 showed weak effects on TGF-b1i n d u c e d
collagen I expression.
Figure 2. Inhibitory effect of PD98059, SB203580 or SP600125
on TGF-b1 induced MAPK pathways phosphorylation in THSF
cells. THSF cells were pretreated with ERK inhibitor (PD98059, 30 mM),
p38 inhibitor (SB203580, 10 mM) or JNK inhibitor (SP600125, 30 mM) for
1 h, respectively. Then the cells were subsequently treated with TGF-b1
(3 ng/ml) for 15 min (A) or 30 min (B, C), followed by protein extraction
and Western blot analysis for total and phosphorylated ERK1/2 (A), p38
(B), and JNK (C). Data are representative of three independent
experiments. *, P,0.05 vs. control; #,P ,0.05 vs. TGF-b1 group.
doi:10.1371/journal.pone.0032128.g002
Figure 3. SP600125 inhibited TGF-b1 induced CTGF expression
and secretion in THSF cells. THSF cells were pretreated with ERK
inhibitor (PD98059, 30 mM), p38MAPK inhibitor (SB203580, 10 mM) or
JNK inhibitor (SP600125, 30 mM) for 1 hour, respectively. Subsequently
they were treated with TGF-b1 (3 ng/ml) for 24 hour. (A) CTGF mRNA
expression levels were detected by real time PCR. (B) CTGF protein was
measured in conditioned medium samples using ELISA and results were
normalized for total protein concentration. Data are representative of
tree independent experiments. *, P,0.05 vs. control; #,P ,0.05 vs. TGF-
b1 group.
doi:10.1371/journal.pone.0032128.g003
JNK Regulates Corneal Scarring
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penetrating corneal wound
We next examined whether JNK was indeed phosphorylated in
response to penetrating corneal wound and the effect of
subconjunctival injection of SP600125 on JNK phosphorylation
in vivo. Expression of p-JNK in the injured corneas was examined
by immunofluorescence analysis. As shown in Figure 5 A, there
was little expression of p-JNK in the cornea of normal rat, whereas
positive p-JNK staining was markedly increased in the corneal
stroma at 1 d after penetrating corneal wound (Figure 5 B). In
SP600125 group, p-JNK expression was significantly reduced
compared with control group received physiological saline
treatment (Figure 5 C). These results suggest that JNK was
activated after injury, subconjunctival injection of SP600125
notably inhibited JNK activation induced by penetrating corneal
wound.
SP600125 inhibited CTGF expression induced by
penetrating corneal wound
To investigate the effect of JNK on CTGF, TGF-b1 expression
after corneal injury in vivo, JNK was inhibited with subconjunctival
injectionofSP600125.ExpressionsofCTGF,TGF-b1mRNAwere
determined by real time PCR analysis and expression of CTGF
protein was determined by immunofluorescence analysis. There
was little expression of TGF-b1, CTGF mRNA in the corneal
stroma without injury. After penetrating corneal wound, TGF-b1,
CTGF mRNA expression markedly increased and reached a peak
at 3 d. Inhibition of JNK with subconjunctival injection of
SP600125, expression of CTGF mRNA was clearly reduced
compared with control group received physiological saline treat-
ment (Figure 6 A), but there was no change of TGF-b1 mRNA
expression between groups (Figure 6 B). Figure 6 C shows that there
was dramatic expression of CTGF protein in the corneal stroma at
3 d after injury. In SP600125 group, expression of CTGF protein
was significantly reduced at 3 d after injury. These results suggest
that inhibition of JNK with subconjunctival injection of SP600125
could inhibit CTGF expression in corneal wound healing, whereas
it did not influence expression of TGF-b1.
SP600125 inhibited corneal scarring in rat corneal wound
healing
Finally, whether inhibition of JNK activation could affect
corneal scarring and corneal wound healing in vivo was
investigated. HE stained histological sections showed that there
were lamellar patterns and ordered collagen fibrils in normal
Wistar rat corneas. As shown in Figure 7, corneal epithelial
healing was almost completed at 3 d in both groups. In control
group, the newly produced corneal stroma was comprised of
disordered collagen fibrils and with loss of normal lamellar pattern.
Whereas in SP600125 group, subconjunctival injection of
SP600125 markedly improved the architecture of cornea and
reduced scarring. In SP600125 group, corneal stroma healing did
not completed at 3 d after injury, but subconjunctival injection of
SP600125 post-wounding daily did not have a significant impact
on wound stroma healing at 14 d and 21 d. These results suggest
that exogenous addition of SP600125 inhibits corneal scarring in
corneal wound healing.
Discussion
The transparency of the cornea is very important for the
maintenance of normal vision. Clinically, the major problem with
corneal healing following injury or surgery is corneal scarring. A
corneal scar may cause hypopsia or even blindness [29]. Fibroblast
proliferation and matrix synthesis induced by growth factors have
been assumed to be involved in initiating and maintaining fibrosis
[30]. Although the underlying mechanisms are complex, many of
the harmful aspects are mediated by the different effects of TGF-
b1 as the final universal pathway. TGF-b1 has been implicated in
many fibrotic disorders of the lung, liver, kidney and pancreas.
Treatment with antisense oligonucleotides or antibodies to TGF-
b1 in cell culture or animal models decreased extracellular matrixc
(ECM) synthesis or reduced scarring. Many of the effect of TGF-
b1 on ECM production, collagen synthesis and cell proliferatio-
nare mediated by CTGF. Namely, CTGF plays a critical role in
mediating the fibroproliferative effects of TGF-b1. Levels of
Figure 4. Effect of MAPK-specific inhibitors on expression of
fibronectin and collagen I induced by TGF-b1 in THSF cells.
THSF cells were pretreated with ERK inhibitor (PD98059, 30 mM),
p38MAPK inhibitor (SB203580, 10 mM) or JNK inhibitor (SP600125,
30 mM) for 1 hour, respectively. Subsequently they were treated with
TGF-b1 (3 ng/ml) for 24 hour. Expression of fibronectin and collagen I
protein was determined by Western blot analysis. (A) SB203580 or
SP600125 significant inhibited TGF-b1 induced fibronectin expression.
(B) SP600125 significant suppressed TGF-b1 induced collagen I
expression. Data are representative of three independent experiments.
*, P,0.05 vs. control; #,P ,0.05 vs. TGF-b1 group.
doi:10.1371/journal.pone.0032128.g004
JNK Regulates Corneal Scarring
PLoS ONE | www.plosone.org 4 February 2012 | Volume 7 | Issue 2 | e32128CTGF are correlated with increased expression of ECM, such as
collagen I, integrins, and fibronectin. Therefore, it is important to
define the signaling pathway through which TGF-b1 induces
CTGF expression.
It is widely accepted that TGF-b1 stimulation results in the
activation of the MAPK pathways [27,31]. The MAPK pathways
are a family of serine threonine protein kinases that are activated
in response to a variety of extracellular stimuli [32]. ERK, p38 and
JNK constitute three major subfamilies of MAPK [33]. ERK plays
a major role in cell proliferation and differentiation, as well as in
survival mediated by various growth factors. JNK and p38 are
activated by various inflammatory cytokines and environmental
stressors and they play important roles in apoptosis and cytokine
production. Studies in renal fibroblasts and mesangial cells
demonstrated the requirement of ERK for TGF-b1 induced
CTGF expression [34,35]. However, in smooth muscle cells both
ERK and JNK are required for CTGF induction by TGF-b1 [36].
In another study using lung fibroblasts, it was determined that
CTGF expression was dependent on JNK, not p38 or ERK [25].
Inhibition of JNK suppressed TGF-b1 induced CTGF and
collagen I expression in mesangial cells [37]. In cultures of human
corneal epithelial cells, synthesis of CTGF induced by TGF-b1i s
through ERK [38]. Studies have shown that there are differences
in the requirement of specific MAPK for CTGF expression
inducted by TGF-b1 and this discrepancy may be explained due
to different cell lines and species.
In our study, THSF cells stimulated with TGF-b1 induced a
rapid activation of ERK, p38 and JNK (Figure 1). Pretreatment of
THSF cells with three MAPK pathways-specific inhibitors
(PD98059, SB203580 or SP600125) could significantly inhibited
the activation of ERK, p38 or JNK, respectively (Figure 2). To
elucidate which member of MAPK may be responsible for the
TGF-b1 induced CTGF, fibronectin and collagen I expression in
THSF cells, activation of p38, ERK and JNK were inhibited by
incubating THSF cells with SB203580, PD98059 and SP600125
for 1 hour before stimulation with TGF-b1, 24 h later expression
of CTGF, fibronectin and collagen I were determined. Our data
showed that inhibition of JNK by SP600125 suppressed expression
of CTGF, fibronectin and collagen I in response to TGF-b1
stimulation, whereas inhibition of p38 by SB203580 only resulted
in suppression of TGF-b1 induced fibronectin expression. On the
other hand, inhibition of ERK by PD98059 did not significantly
alter expression of CTGF, fibronectin or collagen I in response to
TGF-b1 (Figure 3 A, 4). CTGF is a secreted protein. We also
measured the concentrations of CTGF in cell culture superna-
tants. Our data showed that TGF-b1 significantly increased
CTGF secretions and SP600125 markedly inhibited TGF-b1
stimulated CTGF secretion. However, SB203580 or PD98059 had
no effect on the secretion of CTGF induced by TGF-b1 (Figure 3
B). These findings indicate that JNK is a key pathway in
modulating the signals through which TGF-b1 promotes CTGF,
fibronectin and collagen I expression in corneal fibroblasts.
Previous studies demonstrated that inhibition of JNK can
effectively inhibit TGF-b1 induced CTGF expression in corneal
fibroblasts [15,16]. The present results concur with the previous
report and expand the findings by demonstrating that p38 and
ERK are not required for CTGF induction by TGF-b1.
Our group previously demonstrated that TGF-b1 and CTGF
were upregulated dramatically in corneal stroma during corneal
wound healing, CTGF expression decreased dramatically in group
Figure 5. Evaluation of inhibitory effect of SP600125 on penetrating corneal wound induced JNK phosphorylation in Wistar rats. (A)
p-JNK was examined by immunofluorescence analysis. Five micrometer corneal sections were stained with antibodies to p-JNK (green) as well as with
nuclear staining dye (blue). There was little expression of P-JNK in the normal mice cornea of normal rats. (B) Penetrating injury was made in the
central cornea of Wistar rats, control group received daily subconjunctival injection of physiological saline. Positive p-JNK staining was markedly
increased in the corneal stroma at 1 d after injury. (C) Subconjunctival injection of SP600125 notably inhibited JNK activation in the corneal stroma at
1 d after injury. n=4 rat in each group, Bars: 40 mm.
doi:10.1371/journal.pone.0032128.g005
JNK Regulates Corneal Scarring
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subconjunctivaly. TGF-b1 neutralizing antibody may inhibit
the biological functions of TGF-b1. Therefore, we indicated that
TGF-b1 could induce CTGF expression in vivo. To further
investigate the role of JNK in mediating CTGF expression and
corneal scarring in vivo, a penetrating corneal wound model
was created and JNK was inhibited with subconjunctival injection
of SP600125. Immunofluorescence results showed that there
was little expression of p-JNK in corneas of normal rat, but
p-JNK expression was greatly increased in the corneal stroma
after penetrating corneal wound. Subconjunctival injection of
SP600125 could inhibite p-JNK expression compared with
control group received physiological saline treatment (Figure 5).
This indicated that subconjunctival injection of SP600125 could
significantly inhibit activation of JNK induced by corneal
wounding. It was also found that expression of TGF-b1 mRNA,
CTGF mRNA and protein markedly increased in corneal stroma
after injury. Subconjunctival injection of SP600125 could clearly
inhibit CTGF mRNA and protein expression, but did not
influence TGF-b1 mRNA expression (Figure 6). These results
suggest that inhibition of JNK with subconjunctival injection of
SP600125 could inhibit CTGF expression in corneal wound
healing. Histological results showed that the newly produced
corneal stroma was comprised of disordered collagen fibrils and
with loss of normal lamellar pattern in control group, whereas
subconjunctival injection of SP600125 markedly improved the
architecture of corneal stroma and reduced corneal scarring
(Figure 7). The present results indicated that inhibition of JNK
could significantly inhibit corneal scarring after injury. These
findings established that excessive CTGF expression was
responsible for corneal scarring, and inhibition of JNK could
markedly decrease excessive expression of CTGF, and down-
regulation of CTGF expression caused a reduction of corneal
scarring.
It was also found that corneal epithelial healing was almost
complete at 3 d after injury in both groups and subconjunctival
injection of SP600125 did not have a significant impact on wound
stroma healing at 14 d and 21 d. Inhibition of JNK could
effectively reduce corneal scarring without having a deleterious
effect on healing in vivo. Previous reports have indicated that
CTGF cooperates with fibronectin in enhancing the attachment
and migration of human corneal epithelial cells [39]. Also, recent
studies demonstrated that in cultures of human corneal epithelial
cells, TGF-b1 induced CTGF synthesis through ERK and this is
required for cell migration [38]. However, it has been shown that
during re-epithelialisation of mouse corneas, TGF-b1 was found to
Figure 6. Evaluation of inhibitory effect of SP600125 on penetrating corneal wound induced CTGF expression in Wistar rats. (A) Real
time PCR was used to measure CTGF mRNA expression. The expression of CTGF mRNA was upregulated significantly in wounded corneas and
reached a peak at 3 d after injury, subconjunctival injection of SP600125 significantly inhibited injury-induced CTGF mRNA expression. (B) Real time
PCR was used to measure TGF-b1 mRNA expression. Subconjunctival injection of SP600125 did not influence the expression of TGF-b1. Data are
representative of three independent experiments. *, P,0.05 vs. 0 d; #,P ,0.05 vs. control group at the same time point. (C) immunofluorescence was
used to measure CTGF protein expression. Five micrometer corneal sections were stained with antibodies to CTGF (red) as well as with nuclear
staining dye (blue). There was dramatic expression of CTGF protein in the corneal stroma at 3 d after injury. Subconjunctival injection of SP600125
notably inhibited CTGF expression. n=4 rat in each group, Bars: 40 mm.
doi:10.1371/journal.pone.0032128.g006
JNK Regulates Corneal Scarring
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[40].
In summary, the present study demonstrates that TGF-b1 and
penetrating corneal wound induce JNK activation, and JNK
mediates CTGF expression induced by TGF-b1 and penetrating
corneal wound. Inhibition of JNK could inhibit excessive
expression of CTGF and subsequent corneal scarring without
clearly affecting wound healing in vivo. JNK could potentially
serve as a new strategy to reduce corneal scar formation.
Materials and Methods
Animals
Wistar rats (10-week-old male, 200–300 g) were obtained from
the Animal Supplier Center of Shandong University. All the
animal studies were approved by the Ethics Committee of
Shandong University, and animals were used in compliance with
the Association for Research in Vision and Ophthalmology
Statement for the Use of Animals in Ophthalmic and Vision
Research.
Reagents
TGF-b1 was obtained from Peprotech (Rocky Hill, NJ). Anti-
Collagen I antibody was purchased from Abcam (Cambridge,
MA), Antibodies against CTGF, fibronectin were purchased from
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Antibodies
against JNK, ERK1/2, p38 MAPK, phospho-JNK (Thr183/
Tyr185), phospho-ERK1/2 (Thr202/Tyr204) and phospho-p38
MAPK (Thr180/Tyr182) were obtained from Cell Signaling
Technology, Inc. (Danvers, MA). PD98059 and SB203580 were
purchased from Calbiochem (San Diego, CA), SP600125 was
obtained from A. G. Scientific, Inc (San Diego, CA).
Cell culture and treatment
THSF cells were maintained in Dulbecco Modified Eagle
Medium (DMEM; Invitrogen Life Technologies, Carlsbad, CA)
with 10% fetal bovine serum (Gibco, Carlsbad, CA) in a
humidified 5% CO
2 incubator at 37uC. The cells were seeded
into 6-well plates at a density of 2610
5 cells per well in normal
growth medium. Before treatment, the cells were cultured in
serum-free DMEM for 24 h. The cells were treated in the absence
or presence of ERK inhibitor (PD98059, 30 mM), p38 inhibitor
(SB203580, 10 mM) or JNK inhibitor (SP600125, 30 mM) for 1 h,
respectively; TGF-b1 (3 ng/ml) was subsequently added to the
culture for the determined time depending on the different
purposes. The cells of control group were added to an equal
volume of serum-free medium. The culture media and cells were
harvested at the indicated time-points for measurement of RNA
and protein levels.
Enzyme-Linked Immunosorbent Assay (ELISA)
CTGF is a secreted protein, we measured the concentrations of
CTGF in cell culture supernatants by ELISA according to the
manufacturer’s instructions (Uscn Life Science Inc.,Wuhan,
China). Standards were run with each assay to ensure accuracy.
For quantitative results, the signal of unknown samples was
compared against a standard curve. CTGF levels were normalized
for total protein content in the sample using BCA Protein Assay
Kit (Beyotime, Jiangsu, China) and were expressed as ng mg
21
protein for three replicate samples for each condition.
Animal model
The previously described experimental model was used for this
study [41]. Briefly, Wistar rats were anesthetized with chloral
hydrate and placed beneath a stereoscopic microscope. After
instilling Oxybuprocaine Hydrochloride eye drops for local
anesthesia, a penetrating linear incision of uniform size (3 mm)
was made with a scalpel in the center of cornea and treated with
interrupted suture. Erythromycin ophthalmic ointment was
applied for prevention of infection. Only one eye of each animal
was operated, another eye was used as the control. All corneal
surgeries were performed by the same surgeon to ensure
consistency across specimens. The process of corneal wound
healing was observed everyday by slit lamp. Only those corneas
that showed clinically normal healing without complication were
used in this study.
For experimental group, the wounded eyes received subcon-
junctival injection of SP600125 (50 mM) daily after operation.
While control group, the wounded eyes received subconjunctival
injection of physiological saline. The eyes of rats were examined
daily by slit lamp and sacrificed at 1, 3, 5, 7, 14 and 21 days
following the treatment.
HE and Immunofluorescent staining
Histological analysis of the cornea was as previously described
[42]. Briefly, half corneas of rats were fixed in 3.7% formaldehyde
for 24 hours and then were frozen in an optimal cutting
temperature (OCT; Sakura Finetek, Torrance, CA) compound.
Five micrometer corneal sections were sliced with a cryostat. Parts
of the sections were stained with hematoxylin and eosin. Sections
Figure 7. Evaluation of inhibitory effect of SP600125 on
penetrating corneal wound induced corneal scarring in Wistar
rats. A penetrating corneal wound model was created with Wistar rats
and inhibition of JNK activation by subconjunctival injection of
SP600125 daily post-wounding. (A) HE stained histological sections
showed that corneal epithelial healing was almost complete at 3 d in
both groups. Subconjunctival injection of SP600125 after injury daily
markedly improved the architecture of cornea and reduced scarring and
did not have a significant impact on wound stroma healing at 14 d (B),
21 d (C). n=4 rat in each group, Bars: 40 mm.
doi:10.1371/journal.pone.0032128.g007
JNK Regulates Corneal Scarring
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PBS, and primary antibodies were applied overnight in a moist
chamber at 4uC. Fluorescein conjugated secondary antibodies was
applied for 1 hour in a dark incubation chamber at room
temperature. The negative control was prepared by incubation
with secondary antibody alone. HE stain was observed and
photographed using a Nikon UFX-IIA microscope, immunoflu-
orescence stain was examined under a fluorescence microscope.
Every sample was treated simultaneously to reduce variations
among fixation, embedding and section procedures.
Real-time RT-PCR
Real time RT-PCR was performed as previously reported
method [43]. In brief, RNA was isolated with Trizol, 2 mg RNA
was reverse-transcribed using oligo (dT), random hexamers and
Moloney murine leukemia virus (MMLV) reverse transcriptase
(Promega) in a final volume of 20 ml. The resulting cDNA was
used for quantitative real-time PCR with SYBR Green I (Tiangen
Biotech, Beijing, China) on ABI 7000 (Applied Biosystem Inc.,
CA, USA). Primers sequences were: CTGF: forward 59-GCTG-
GAGAAGCAGAGTCGTC-39, reverse 59-CCACAGAACTTA-
GCCCGG TA-39; TGF-b1: forward 59- GTCAACTGTGGAG-
CAACACG-39, reverse 59-AGAC AGCCACTCAGGCGTA-39;
b-actin: forward 59-CGTTGACATCCGTAAAGACC-39, reverse
59-TAGAGCCACC AATCCACA-39. All real-time PCR reac-
tions for each cytokine were performed in triplicate. Gene
expression levels were calculated and normalized by dividing the
calculated values for the mRNA samples by that of b-actin mRNA
at the same time point.
Western blot analysis
Western blotting proceeded as previously described [44].
Briefly, cultured cells were collected at the indicated times and
lysed by shaking at 4uC for 30 min in RIPA buffer (50 mM Tris-
HCl, 1% NP-40, 0.25% Na-deoxycholate, and 150 mM NaCl,
1m MN a 3VO4 and NaF) containing protease inhibitors (1 mg/ml
each of EDTA and phenylmethylsulfonyl fluoride). Cell lysates
were centrifuged at 12,000 g for 15 min at 4uC. The supernatant
was transferred to new Eppendorf tubes (Zhizhuang Biotech, Co.,
Ltd., Shanghai, China) and boiled for 5 min in sample buffer
(12 mM Tris-HCl, 10% glycerol, 10% sodium dodecyl sulfate and
1% 2-mercaptoethanol and 0.1% bromophenol blue, pH 6.8).
Total protein was quantified and 30 mg protein samples were
subjected to 10% sodium dodecyl sulfate-polyacrylamide gel
electrophoresis, and then transferred to nitrocellulose membranes.
The membranes were blocked with 5% skim milk in Tris-buffered
saline containing 0.05% Tween-20 for 2 h at room temperature
before overnight incubation at 4uC with primary antibodies. After
incubation with primary antibodies, nitrocellulose membranes
were extensively washed with Tris-buffered saline with 0.05%
Tween-20 and incubated with secondary antibodies for 2 h at
37uC. Protein bands were visualized using enhanced chemilumi-
nescence as described by the supplier (GE Healthcare). Densito-
metric analysis has been carried out with Quantity One software
(Bio-Rad, Hercules, CA).
Statistical analysis
Results were expressed as means 6 SD. Student’s t-test was
used to compare two groups of Results, whereas ANOVA was
used in multiple group comparisons. P,0.05 was considered
statistically significant. Data analysis was carried out with the
Statistical Package for Social Sciences (SPSS version 11.0).
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